NHS Digital Data Release Register - reformatted

Queen Mary University of London

Project 1 — DARS-NIC-12629-B4N5K

Opt outs honoured: Yes - patient objections upheld (Section 251)

Sensitive: Sensitive, and Non Sensitive

When: 2019/01 — 2019/03.

Repeats: One-Off

Legal basis: Health and Social Care Act 2012 – s261(7)

Categories: Identifiable

Datasets:

  • MRIS - Members and Postings Report
  • Hospital Episode Statistics Accident and Emergency
  • Hospital Episode Statistics Outpatients
  • Hospital Episode Statistics Admitted Patient Care
  • MRIS - Cause of Death Report
  • MRIS - Cohort Event Notification Report

Yielded Benefits:

Registry data provided to date has identified numerous cases of breast cancers, other cancers and side-effects in participants with whom the Centre for Cancer Prevention at Queen Mary University London have no direct contact and therefore not already known by the study team. Collection of this data has contributed directly to the primary endpoints of the trial and will continue to provide valuable information on the long-term risk/benefit status of the trial intervention. This long term data is essential for informing bodies such as NICE to inform the prescribing utility of these drugs as chemopreventive agents. The CCP use registry reported events as a prompt for further investigation by asking participants' current GP practice to confirm the event and also provide any further information e.g. cancer grade, size, receptor status that is required to meet secondary and exploratory objectives. So far the long-term follow-up has shown that tamoxifen significantly reduces breast cancer incidence in women at risk of developing the disease. The thromboembolic side effects and increase in gynaecological problems (including endometrial cancer) disappear after the active treatment phase has ended. The trial has also provided further information on the impact of tamoxifen on breast density: mammographic density appears to be a prognostic marker for improved long-term survival in participants receiving adjuvant tamoxifen. Notably, the IBIS-I study won the Cancer Research UK Prize for Translational Cancer Research at the 2014 NCRI Cancer Conference for its improvements in cancer research (http://www.ibis-trials.org/thetrials/ibistrials/ibis-i-award). Moreover, NICE updated its guidelines on prescription of tamoxifen to women at high risk of developing breast cancer, a decision partly based on results of the IBIS-I Study (first published June 2013, update August 2015; https://www.nice.org.uk/guidance/CG164 and https://www.nice.org.uk/guidance/cg164/evidence/surveillance-review-decision-november-2015-pdf-2178797581).

Objectives:

Established in 1992, the IBIS-I Study investigated the efficacy of tamoxifen (a hormonal drug used to prevent breast cancer) versus a placebo drug (taken daily for five years) in terms of reduction of breast cancer incidence in pre and post-menopausal women at high risk of developing breast cancer. It was a double-blind, randomised placebo-controlled trial that recruited 7,154 women internationally (of which 4,277 were UK participants), aged 35-70 years. The primary outcome measure was the incidence of breast cancer, including ductal carcinoma in situ (cancer cells in the lining of the breast milk duct) and side effects present in the patients were also investigated. Recruitment to the study completed in 2001 and the intervention (placebo/tamoxifen) ended in 2007. In early 2008 the Research Ethics Committee (REC) approved the conversion of IBIS-I to an epidemiological cohort study. During 2007–2016 participants were followed-up via an annual postal questionnaire. In 2002, initial results found that tamoxifen reduced the risk of invasive breast cancer by 31%. Mortality from non-breast-cancer causes was not increased by tamoxifen. However, the analysis concluded that the overall risk/benefit ratio for the use of tamoxifen in prevention remained unclear and that continued follow-up of trial participants was essential. A 2007 analysis on long-term tamoxifen prophylaxis for breast cancer confirmed the preventive effect of tamoxifen in terms of breast cancer incidence and that this was constant for the entire follow-up period. No reduction in size of benefit was observed for up to ten years following participant randomisation. Additionally, tamoxifen-related side effects such as thrombo-embolism were not increased anymore after the 5-year treatment period. These results therefore demonstrate that the benefit-to-risk ratio of tamoxifen improves with increasing duration of follow-up. Thus, how much additional benefit will be seen long-term remains an important question. Based on these above-mentioned results, the Central Coordinating Office (CCO) at the Centre for Cancer Prevention (CCP) at Queen Mary University London (QMUL) seek to continue to passively collect cancer registration and mortality data via MRIS products provided by NHS Digital, and to also start collecting Hospital Episode Statistics (HES).The data sets returned by NHS Digital will provide vital information on side effects, survival and breast cancer incidence. These data are essential in enabling the CCO to determine whether tamoxifen continues to have a long-term beneficial impact in terms of breast cancer incidence, survival and side effects after the initial 5-year treatment period. The CCO will be able to perform a thorough risk-benefit assessment of tamoxifen and a 30-year median follow-up analysis. These analyses will enable the research community to make more informed decisions on tamoxifen vis-a-vis patient safety and both short- and long-term effectiveness. The results so far have been very important for breast cancer in the preventive setting.

Expected Benefits:

The data sets returned by NHS Digital will provide vital information on side effects, survival and breast cancer incidence. IBIS-I is currently the only cancer prevention study to have achieved a 20 year follow-up so far. Using these data sets, the IBIS-I Central Coordinating Office (CCO) will conduct research and analyses that will help provide further information on: • the efficacy of tamoxifen prophylaxis in reduction of the risk of breast cancer in high-risk women (pre- and post-menopausal); • the safety of tamoxifen prophylaxis in reduction of the risk of breast cancer in high-risk women (pre- and post-menopausal); • the long-term all-cause mortality rate related to tamoxifen; • a thorough risk-benefit assessment of tamoxifen. The research will help further inform public health bodies such as NICE on the safety and efficacy of tamoxifen as a chemopreventive agent. These analyses will enable patients and women at risk of developing breast cancer to make a more informed decision on the preventive treatment options available to them. An estimated 15% of women in the UK could benefit from preventive tamoxifen therapy and therefore results from the IBIS-I study are of great relevance to these women. The target date for these benefits is anticipated in 2019 and 2025, in line with the anticipated analyses of the 20 and 25 year follow-ups respectively.

Outputs:

The first results of the IBIS-I have already been published (Cuzick J, et al. The Lancet. 2002;360: 817-24; Cuzick J, et al. J Natl Cancer Inst. 2004;96:621-628; Cuzick J, et al. J Natl Cancer Ins. 2007;99:272-82; Cuzick J, et al. San Antonio Breast Cancer Symposium. 2014, Dec 9-13; Cuzick J, et al. Lancet Oncol. 2015;16(1):67-75). Further outputs and analyses of the IBIS-I trials will be published in peer-reviewed medical journals such as The Lancet, The Lancet Oncology, Breast Cancer Research and Treatment and the British Journal of Cancer with at least two anticipated publication dates in 2020 and 2025 Outputs are anticipated in 2019 when there is 20 years of median follow-up data available. It is further anticipated that Queen Mary University of London will run an updated analysis in 2024 (25 years median follow-up). The public will be made aware of the research progress through two web pages (http://www.ibis-trials.org/thetrials/yourstories/press-articles and http://www.wolfson.qmul.ac.uk/current-projects/ibis-1#publications), and also via updates on Twitter (https://twitter.com/qmccp). The anticipated audiences of the above outputs are researchers, scientists, stakeholders for the wider project and research participants. Policy makers - such as NICE will also be targeted with the outputs of the study. NICE will be informed on the safety and efficacy of tamoxifen as a chemopreventive agent, allowing more information available to women at risk of developing breast cancer on the options available to them. An estimated 15% of women in the UK could benefit from preventive tamoxifen therapy and therefore results from the IBIS-I study are of great relevance to these women. Data contained in any outputs will be aggregated with small numbers suppressed in line with the HES analysis guide.

Processing:

All organisations party to this agreement must comply with the Data Sharing Framework Contract, including requirements on the use (and purposes of that use) by “Personnel” (as defined within the Data Sharing Framework Contract i.e.: employees, agents and contractors of the Data Recipient who may have access to that data). The Centre for Cancer Prevention at QMUL will send IBIS-I cohort data, i.e. a list of IBIS-I study participants, to NHS Digital for linkage. The following identifiers will be sent to NHS Digital by the CCP team at QMUL: -Full Name, -Date Of Birth, -NHS Number, -Postcode, -Study ID. The data received by the Centre for Cancer Prevention at QMUL will not be used for any purpose other than to meet objectives as stated in the trial protocol and will not be shared with any other third party or organisation. The data sets returned by NHS Digital to QMUL will contain identifiable data. This is so that the applicant can confirm the accuracy and strength of each linkage for IBIS-I participant in the study cohort. This ensures that all side effects, survival and cancer incidence data are correctly attributed to the each IBIS-I participant, thus avoiding any errors which would invalidate the study. On receipt of the returned data set from NHS Digital, the Centre for Cancer Prevention at QMUL will link this data set to the data set contained in the applicant's IBIS-I study database via the full name, date of birth, NHS number and study ID. As mentioned, the data linkage enables the correct identification of the IBIS-I patients from the data set sent by NHS Digital. Once the patients are identified, researchers at QMUL will then update the participant entries in the IBIS-I study database with date and cause of death, cancer recurrence, diagnosis and coding, and any HES data relevant to the study (fractures, cardiovascular and thrombo-embolic events). Following the linkage and participant identification, all identifiers except the study ID will be removed from the data set returned by NHS Digital and stored as a reference for analysis until study completion. Following receipt of the data sets by NHS Digital, if further information is required in addition to that provided from the HES/Mortality data sites, the IBIS-I CCO will request supporting information from the participant's general practitioner (GP) or IBIS-I study file. The supporting information requested by the IBIS-I CCO would comprise cancer recurrence (i.e. grade, site, receptor status) and side effects (i.e. fractures, cardiovascular events, thrombo-embolic events). The s251 support covers the linkage to the GP data. Additionally, the IBIS-I Informed Consent Form (version dated 26/10/2001), approved by the REC, informed the participant that the above-mentioned further details will be requested from their GP. Processed data sets with all identifiers removed except the Study ID will be retained for analysis until study completion, following which it will be archived for 20 years. The original 'raw' data set returned by NHS Digital containing identifiable data will be stored on a separate server meeting NHS Digital security requirements, as per DARS Guidance Notes on Security for where Mortality data is involved. The applicant would like to emphasise that data is stored on the secure network and never on the local drives of unencrypted QMUL desktop PCs. QMUL creates back-ups of the data stored on its network. The encrypted backup tapes are stored offsite with Iron Mountain UK Ltd. The data is not accessible by any Iron Mountain employee. All personal identifiable data received at the Centre for Cancer Prevention are stored electronically on a database, local to and administered by substantive employees of QMUL only. Personal identifiers of study participants are stored separately to the clinical data, with access strictly restricted to only QMUL substantive members of staff. Only these members of staff will have access to the personal identifiable data. Additionally, access to the personal identifiers on the Oracle database is controlled by separate username and password access and is controlled by the IT Department. The separate Mortality and HES servers are self-contained within the Centre for Cancer Prevention network within the QMUL network. They are firewalled from external connections and the rest of the network. All traffic through the checkpoint firewall is logged. Access to data will be from within the network using workstations that have a currently supported operating system which includes security patches. Users are not permitted to download the data from these workstations. No remote access (i.e. through a VPN/RDP connection) is permitted. No mobile devices will be used to access any data. The network is externally scanned on a regular basis. The 'raw' data sets will be stored until the data destruction date as per this agreement with NHS Digital. The storage architecture is compliant with the NHS Digital Data Sharing Framework Contract and once QMUL is issued with a Data Destruction notice, the data from all storage including backups can be securely and permanently removed within 14 days. Data can be securely wiped to NHS Digital standards (multi pass pattern wiped to at least HMG S5 Enhanced on site and if end of life, degaussed and physically destroyed). Under this agreement, it is not permitted so share the "raw" data with international partners. Only aggregated data with small numbers suppressed in line with the HES Analysis Guide is permitted to be shared.


Project 2 — DARS-NIC-147843-8NKTW

Opt outs honoured: Yes - patient objections upheld (Section 251)

Sensitive: Sensitive

When: 2016/04 (or before) — 2019/03.

Repeats: Ongoing

Legal basis: Section 251 approval is in place for the flow of identifiable data, Health and Social Care Act 2012 – s261(7)

Categories: Identifiable

Datasets:

  • MRIS - Cause of Death Report
  • MRIS - Cohort Event Notification Report
  • MRIS - Scottish NHS / Registration

Yielded Benefits:

No outputs have been produced as the data analysis plan was designed such that no analysis would be undertaken until sufficient numbers of stomach cancers had occurred. The numbers reported are not sufficient yet.

Objectives:

The aim of the trial is to determine whether healthy people should be screened and treated for H Pylori infection.

Expected Benefits:

If the trial determines that screening and subsequent eradication of H Pylori reduces the incidence of stomach cancer this will have an enormous benefit to the whole population in the UK and worldwide. Both screening and eradication (a 1 week course of antibiotics) are simple and cheap. Around 40% of people have H Pylori infection. In 2015 6740 people developed stomach cancer. If screening does work and prevents 20% of stomach cancers then this will mean that over 1,300 stomach cancers will be prevented. With 4 out of 10 people in the UK thought to have H Pylori infection potentially 40% of the population could have their risk of stomach cancer reduced. The extension of our data sharing agreement will allow us to obtain enough cases of stomach cancer to provide the information needed on the value of screening. This trial will provide evidence concerning whether screening for HPylori infection is worthwhile. If the results from the trial are positive then we would be in a position to contact PHE to discuss implementing a population screening programme.

Outputs:

The following outputs will be produced : A peer review paper analysing the results from the trial will be submitted to an open-access peer reviewed journal within one year after sufficient stomach cancers have occurred.This paper should be influential in deciding whether to screen for H Pylori infection . The final report of results will be submitted to CRUK. This will cover all findings of the study. For each paper published, a short presentation may be developed to summarise the findings for a range of stakeholders, including healthcare professionals and patient groups. The study website will provide links to the open access papers and will offer free downloads of accessible summaries of findings. All outputs will contain only data that is aggregated with small numbers suppressed in line with the HES Analysis Guide/compliant with the MHSDS disclosure control rules including suppression and rounding.

Processing:

All 62,454 participants in the HPSS have been flagged at NHS Digital. Information on deaths and cancer registrations is requested to be received every 6 months electronically. The electronic information will be downloaded onto a secure server, protected by a fire-wall, based in the Wolfson Institute of Preventive Medicine. The data are then merged with the HPSS study database by the database manager in the Wolfson Institute. The data are stored on the server, with any identifiers stored separately from the clinical information. The database manager provides the study statistician with pseudonymised information on the numbers of deaths and cancer registrations that have occurred since the start of the trial. Data will only be accessed by individuals within the Centre for Environmental and Preventive Medicine who have authorisation from the PI (Sir Nicholas Wald) to access the data for the purpose described, all of whom are substantive employees of QMUL. The core dataset will only be accessed by the data manager within the Wolfson Institute. They will produce subsets of the data that will be accessed by the study statistician. Any other person seeking access toi a subset of the data will have to submit a formal reuest to the PI (Sir Nicholas Wald) and justify from a scientific basis all requested information. All organisations party to this agreement must comply with the Data Sharing Framework Contract requirements, including those regarding the use (and purposes of that use) by “Personnel” (as defined within the Data Sharing Framework Contract i.e.: employees of QMUL situated in the Centre for Environmental and Preventive medicine who may have access to that data). No further linkage will be performed. The data will not be made available to any third parties other than those specified except in the form of aggregated outputs with small numbers suppressed in line with the HES Analysis Guide. Data is only requested for those participants in the HPSS study. Some identifiers are necessary to ensure that the correct match with the study participant is made. The BUPA identifiers which were used in this study were not totally unique, causing manual checks to be made when any linkage is performed. No outputs have been produced as the data analysis plan was designed such that no analysis would be undertaken until sufficient numbers of stomach cancers had occurred. The numbers reported are not sufficient yet.


Project 3 — DARS-NIC-25945-T8Q0Z

Opt outs honoured: N

Sensitive: Sensitive

When: 2016/09 — 2017/02.

Repeats: Ongoing

Legal basis: Informed Patient consent to permit the receipt, processing and release of data by the HSCIC

Categories: Identifiable

Datasets:

  • MRIS - Flagging Current Status Report
  • Hospital Episode Statistics Admitted Patient Care
  • Hospital Episode Statistics Accident and Emergency
  • Hospital Episode Statistics Outpatients
  • MRIS - Cohort Event Notification Report

Objectives:

The BEST2 study was set up to investigate the safety and performance of the Cytosponge™ test for diagnosing Barrett's Oesophagus (BE) over three years. It is a case-control study, participants (1344 men/women aged 18-60 years) are either patients with known BE (860) or controls individuals' with reflux or indigestion (dyspepsia) symptoms referred for endoscopy (484). All participants swallowed a Cytosponge™ device prior to endoscopy, which is processed for a number of different biomarkers. Results are then compared with endoscopy findings. After the first year of study all cases completed Cytosponge™ and endoscopy procedures. The BEST2 study would like to follow-up participants using HES information in order to collect long-term efficacy and safety data. The main objective is to assess the reproducibility and efficiency of the Cytosponge™ procedure and results to determine the risk of cancer progression, and to compare with endoscopic biopsies, for potential use in the NHS or other health care setting. The Cytosponge™ test showed a specificity of 92% and a sensitivity of around 80% which increases with segment length and is not compromised in the presence of dysplasia. The Cytosponge™-TFF3 test could be used to diagnose patients who would otherwise be referred to endoscopy to rule out BE and therefore be a more systematic screening test for use in primary care. Follow up of all participants is needed to continue monitoring the presence of dysplasia and any risks of cancer progression. Currently guidelines recommend endoscopic screening for BE in individuals with multiple risk factors. However, the cost advantages associated with the Cytosponge™-TFF3 test means screenings could be offered to a larger number, thereby improving the potential to correctly identify a greater amount of newly diagnosed BE cases. The BEST2 study trial site (Cambridge) propose to provide the identifiable data to HSCIC, for all participants that have consented to this, for linkage. HSCIC will return the linked data set with any patient identifiable information (NHS number, names etc) that Cambridge previously sent to the HSCIC along with requested data sets. Identifiable data is requested so that Cambridge can update any new information on the cohort in order to contact participants. Cambridge will not contact the patients directly but will inform the participants GP who in turn will discuss with the participant. Cambridge will then send a patient level pseudonymised version of this data set to QMUL for further processing linked using a unique study ID. Data linkage will improve the quality and integrity of data already collected. All clinical data received, will be stored in a distinctly separate database to the patient identifiable data. The data will not be used for any purpose other than to meet objectives as stated in the trial protocol & will not be shared with any third party organisation. Any information which is used for publication in peer reviewed journals will be anonymised (i.e. aggregated data) & not presented at the individual level.

Expected Benefits:

The BEST2 study recruited 1344 men and women within the UK with either known Barrett's Oesophagus (cases) or individuals with reflux or indigestion symptoms referred for endoscopy (controls). All participants were screened with the Cytosponge™ device to test its potential in determining the risk of cancer progression (in conjunction with biomarkers of risk). The results were then compared to routine endoscopy findings. The study objectives are as follows: Primary objectives QMUL are interested in obtaining the data from these patients to link the biomarker work performed on the samples collected and the risk of progression to cancer. Performance and safety characteristics of the Cytosponge™ test Effectiveness of the Cytosponge™ for diagnosing BE compared with endoscopy, including specificity (from controls) and sensitivity (from cases) For patients with BE, the ability of Cytosponge™ biomarkers to risk stratify patients, according to their future cancer risk in comparison with the dysplasia grade obtained from endoscopic biopsies. Secondary objectives Differential sensitivity of screening BE with dysplasia (low and high grade) compared to non-dysplastic BE. Determine the reproducibility of the Cytosponge™ result by repeated testing in a subset of individuals Logistics of high-throughput sample processing and automated analysis of Cytosponge™ specimens for use in routine NHS or other health care settings. Surplus material will be used for testing emerging biomarkers. Analysis of NHS records will help measure long term effectiveness of the Cytosponge biomarkers to risk stratify patients. In addition to identifying its efficacy in an NHS setting as an alternative to endoscopies. The potential benefits of this research include reducing the use of invasive procedures for patients and by providing evidence for policy decision makers for the use of a safe, minimally invasive, cheaper, and easily administered method to diagnose and screen for this condition A target date has not yet been assessed due to the unknown level of data expected to be received as processing time cannot be estimated yet.

Outputs:

Data outputs produced will not contain any patient identifiable data or be shared with any third party organisation. The only outputs produced will be publications for research purposes using aggregated data with small number suppression in line with the HES Analysis Guide. At this point in time, QMUL cannot comment on the name of journal or conferences as it will depend on the result. Possible journals include PLOS Medicine, Gastroenterology or Gut. The conferences would be Digestive Disease Week and/or United European Gastroenterology Week. It is not yet possible to give a time frame as the length of time to obtain the data has already extended longer than anticipated but once data has been received QMUL expect processing to be completed in around 4-6 months.

Processing:

The data will be processed jointly by Cambridge university and the data controller QMUL. Cambridge university will send the cohort data to the HSCIC for data linkage. Once returned from the HSCIC Cambridge will integrate the data into their database updating any new patient information. Then the identifiable information received from the HSCIC will be removed by Cambridge and this anonymised data set will be sent (via secure encrypted data transfer) to QMUL linked via a unique identifier. QMUL will use this data to link baseline Cytosponge™ findings to disease progression. The following outcomes will be monitored; Barrett’s oseophagus, Barrett’s high grade dysplasia, adenocarcinoma of the oesophagus, squamous cell carcinoma of the oesophagus and oesophageal cancer. All data received at the QMUL Centre for Cancer Prevention, (CCP), are stored electronically on an Oracle database (Oracle 11g). The system is self-contained within the Barts Cancer Research Centre (QMUL) network, within the Queen Mary University of London (QMUL) network, but firewalled off from the rest of the network, in addition to external connections.


Project 4 — DARS-NIC-291938-R6V3V

Opt outs honoured: Y, No - consent provided by participants of research study (Consent (Reasonable Expectation))

Sensitive: Sensitive, and Non Sensitive

When: 2016/04 (or before) — 2019/03.

Repeats: Ongoing, One-Off

Legal basis: Informed Patient consent to permit the receipt, processing and release of data by the HSCIC, Health and Social Care Act 2012 – s261(2)(c)

Categories: Identifiable

Datasets:

  • MRIS - Cause of Death Report
  • MRIS - Cohort Event Notification Report
  • MRIS - Flagging Current Status Report
  • MRIS - Members and Postings Report

Yielded Benefits:

The DARE study has contributed to the recruitment of over 25 ethically approved NIHR portfolio studies to date and has involved the participation of over 2,200 people registered on the database. These studies are aimed at either finding a cure for diabetes or improving health of those with diabetes. Having this database has accelerated the research process and provided evidence which has improved health care provision. For example, the team recently searched for a study called REVITA-2. This study for over weight people with type 2 diabetes (T2D) is trialling a new investigative procedure in the small intestine (duodenum). The study is designed to safely alter the inner surface of the duodenum to improve control of blood sugar. The study was very difficult to recruit to. Using DARE the Team were able to identify nearly 200 people meeting the criteria with 5% of these going on to be screened into the study. The benefit for DARE members is that they have access to some of the latest research studies which they may be interested in. The yielded benefit to the company is that they will now be undertaking another study - REVITA -3 which will improve the health of many others with T2D. In another completely different study DARE members were also contacted about a questionnaire - the Diabetes Essential Care Study - which asked their opinion about Diabetes Care provision in primary care. So far nearly 2000 people have responded and presentations have been made on preliminary findings to the study steering committee. The next yielded benefit is to make reports to local CCGs on the findings which could have a beneficial affect on service provision. All outputs will be aggregated with small numbers suppressed in line with the HES Analysis Guide.

Objectives:

The aim of this study is to establish an epidemiologically based sample of all patients with diabetes within the regions included in the Diabetes Research Network (DRN). By collecting the same non-invasive samples as per clinical care it will be possible to perform tests to look for markers of the complications of diabetes. DNA will be taken from all consenting patients and molecular and genetic information will be combined with clinical information to provide a resource to look for gene/environment interaction in the development of Type 1, Type 2 and other forms of diabetes and their associated complications. Data access is restricted to those named in section 7 of this agreement. Any changes will be notified to the HSCIC.

Expected Benefits:

The expected benefit of the DARE database is that study team can continue to offer people registered the opportunity to take part in diabetes research. Recruitment is sometimes a difficult aspect of any research and can be costly in terms of searching and advertising. Studies using the database can expect to have an increased chance of recruiting more efficiently and quickly. This speeds up the evidence gained from the research and may lead to prompt changes in treatment and care, improving self management etc. The indirect expected benefit of being on the DARE database is that many members are likely to attend outreach events organised by the study team and have access to new information about their diabetes which in turn improves health and well being for people with diabetes.

Outputs:

The main output is an up-to-date database for the DARE study which means that the study team can contact their members about research opportunities when they become available. They will also be holding a series of public engagement events with researchers and clinicians. The first such event was on 13th November 2018 where they invited people from the database to listen to presentations on diabetes research which they may be interested in. The event was also attended by the charity Diabetes UK and latest information on diabetes and self management was distributed. Members were also allowed to vote on future presentations and make recommendations. The day was highly evaluated and a report was sent to all invited members. The study team also have a twitter account to promote such events. Another large event is being planned in the autumn of 2019. The study team also intend to email and post a twice yearly newsletter giving latest information on diabetes research and other relevant material to members. The first newsletter is anticipated to be in Spring 2019. It is the study team's intention to submit abstracts and presentations for relevant diabetes professional conferences e.g. Diabetes UK and International Diabetes Federation and publish our findings in appropriate journals e.g. Diabetic Medicine. All outputs will be aggregated with small numbers suppressed in line with the HES Analysis Guide.

Processing:

No contact will be made with any individual(s) who could be identified from the information supplied, other than as specified in the protocol and associated documents. Use of the data supplied is for the sole purpose set out above. The Data must not be shared with any other organisation or named individual not explicitly referred to within this agreement. If the information referred to herein is subject to an FOI or other request to share the Data, then agreement from the HSCIC must be sought before undertaking this. The Dataset must not be shared with any third party in the format in which it is provided to you by the HSCIC. Information tools derived from this Dataset will not be provided to any organisations without the specific consent of the HSCIC. Any publications derived from this Data by any party must be subject to ONS confidentiality guidance on the release of birth and death and Health Statistics: The National Statistician sets standards for protecting confidentiality, including a guarantee that no statistics will be produced that are likely to identify an individual unless specifically agreed with them, where the guarantee is judged against the standard that ‘it would take a disproportionate amount of time, effort and expertise for an intruder to identify a statistical unit to others, or to reveal information about that unit which is not already I the public domain.’ Specifically, undertake to ensure that appropriate controls are in place, to ensure compliance with the HSCIC’s, Small Numbers Special Terms and Conditions. Such controls will, as a minimum, meet the requirements of condition 3.3 of the Small Numbers Special Terms and Conditions and more generally satisfy Section 5 of the ONS confidentiality guidance.


Project 5 — DARS-NIC-324220-P6W9Y

Opt outs honoured: Y

Sensitive: Sensitive, and Non Sensitive

When: 2016/04 (or before) — 2018/02.

Repeats: Ongoing, One-Off

Legal basis: Section 251 approval is in place for the flow of identifiable data, Approved researcher accreditation under section 39(4)(i) and 39(5) of the Statistical Registration Service Act 2007

Categories: Identifiable, Anonymised - ICO code compliant

Datasets:

  • MRIS - Flagging Current Status Report
  • MRIS - Cause of Death Report
  • Hospital Episode Statistics Admitted Patient Care
  • Hospital Episode Statistics Accident and Emergency
  • Hospital Episode Statistics Outpatients
  • MRIS - Cohort Event Notification Report
  • MRIS - Scottish NHS / Registration

Objectives:

Purpose The Data Recipient agrees to process the Data only for the following purposes agreed with the HSCIC: Objective for processing: The International Breast Cancer Intervention Study (IBIS-II) Prevention & DCIS (Ductal Carcinoma In-Situ) studies were designed to continue the work started by IBIS-I in determining whether a chemo preventive strategy towards breast cancer is beneficial. Both are double-blind, placebo controlled, randomised trials, which recruited post-menopausal women between the ages of 40 & 70. It is the intention to collect data for these cohorts regarding breast cancers, including recurrences, through the use of HES and ONS data, in order to assess efficacy, and meet the primary and secondary objectives of the trial. The primary objective is to determine the long-term effect of using anastrozole and assess if it is at least as effective as tamoxifen in local control and prevention of contra-lateral disease in women with locally excised estrogen receptor (ER) or progesterone receptor (PgR) positive cancer tumors. The participants HES/ONS data will be used to compare the effects and effectiveness of the two drugs used in the intervention (tamoxifen and anastrozole). The study will observe the patients data for any cancer occurrences or serious medical illnesses that occurred each year during the study (intervention arm 2000-2010) tracking notable changes in health their status. Secondary objectives of the study are: i. To examine the rate of breast cancer re-occurrence and new contra-lateral tumors after cessation of tamoxifen or anastrozole. ii. To examine the effect of tamoxifen versus anastrozole on breast cancer mortality Data received from the HSCIC will be used to examine the health statuses of each participant following the end of their taking of the drug to present day and ongoing for long-term analysis. Furthermore, long-term use of anastrozole has been linked to increased fracture rates and research has indicated there are risks of cardiovascular events associated with radiotherapy, a treatment which some of the (Ductal carcinoma in situ) DCIS participants may have undergone. This highlights a vital need for passive follow-up to obtain important safety data regarding other cancers, cardiovascular & thromboembolic events, and fractures, from inpatient, outpatient and A&E records. To measure this the applicant will observe the number of fracture, cardiovascular and thrombolic events that occurred throughout the duration of the study period and after in order to build a profile of possible side effects for each drug.

Expected Benefits:

Expected measurable benefits to health and/or social care including target date: 1.1. Primary 1. Following completion of the analysis (duration one year from data received) the customer will be able to publicise the effectiveness of cancer prevention drugs tamoxifen and anastrozole in reducing the occurrence of cancer. 2. To compare any potential or serious side effect from using either tamoxifen or anastrozole for a long period of time 1.2. Secondary 1. To examine the rate of breast cancer recurrence and new contralateral tumors after cessation of tamoxifen or anastrozole. So it can be observed if cancer rates will increase after one has stopped using the medication 2. As the drugs administered in this trial are still widely used it will benefit the public to have a clear understanding if there are any long term issues linked to using the drug and cardiovascular disease, fracture rates and non-cancer deaths. There is considerable interest in the trial from Cancer Research UK who are funding the study the steering committee is co-Chaired by a representative from CRUK. The publication and findings from HSCIC data will be used to inform our studies drug providers the overall impact and effectiveness of their drugs including long-term side effects.

Outputs:

Specific outputs expected, including target date: Data outputs produced will not contain any patient identifiable data or be shared with any third party organisation. The only outputs produced will be publications (medical journals; The Lancet, Breast Cancer research and treatment, British Journal of Cancer) for research purposes using aggregated data or small numbers suppressed derived from our findings at the most. These will be delivered over a 10-year period. The data will not be used for any purpose other than to meet objectives as stated in the trial protocol & will not be shared with any other organisation. Any information which is used for publication in peer reviewed journals will be anonymised & not presented at the individual level .The study estimate that the research will be complete following 9 months after the date that the first dataset received. Any comparisons between findings from other studies or countries will be made the aggregated level and under no circumstances will identifiable data be used for this or in any publications. Only the members of the study will have access to the direct outputs received suppressed in line with HES analysis guide from the HSCIC

Processing:

Processing activities: QMUL will send the IBIS-II cohort data (list of participants on the IBIS-II study) the legal basis for the cohort is Section 251 (Full name, DOB, NHS number) to HSCIC for data linkage. QMUL will use the returned data set to link baseline study findings with potential cancer progression and any occurrence of serious adverse events identified by HES, ONS or cancer registry data. The identifiable data will be used to confirm the strength of each linkage. This ensures that no incorrect diagnoses are made which would invalidate the study. Patient HES/ONS data will be electronically stored on an Oracle database (Oracle 11g). the system is self-contained within the Barts Cancer Centre QMUL network and firewalled off from the rest of the network and external connections. This only allows access for those members mentioned on this applications. No data held from IBIS-I will be used as any part of this study. IBIS-I and IBIS-II are two separate studies run in parallel. QMUL will use the returned data set to link baseline study findings with potential cancer progression and any occurrence of serious adverse events identified by HES, ONS or cancer registry data. Data will be analysed by the study to ascertain how many cancers and/or serious adverse events have occurred since baseline. The applicant will also look at any adverse outcomes such as death in patients who are using anastrozole. This analysis will only make use of the unique study identifier to match each participant to their health record from this stage onwards PID will not be analysed.


Project 6 — DARS-NIC-37666-Z1C3M

Opt outs honoured: Yes - patient objections upheld (Section 251)

Sensitive: Sensitive

When: 2019/02 — 2019/03.

Repeats: One-Off

Legal basis: Health and Social Care Act 2012 – s261(7)

Categories: Identifiable

Datasets:

  • MRIS - Flagging Current Status Report
  • MRIS - Cause of Death Report

Objectives:

Breast cancer is increasingly becoming a “survivable” disease, and an increasing number of recurrences occur late, so that there is much interest about the long-term efficacy and safety of treatments. The Oxford Overview process has provided useful data on follow-up for 15-20 years after tamoxifen therapy. Such data are lacking for the newer aromatase inhibitors (AIs). This study provides a unique opportunity to address this issue. The ‘Arimidex, Tamoxifen, Alone or in Combination’ (ATAC) trial is the vanguard breast cancer trial for the use of AIs in the adjuvant setting, with a median follow-up of 100 months. Established in 2010, the Long-term Anastrozole vs Tamoxifen Treatment Effects (LATTE) observational study aims to collect vital long-term safety and efficacy data on anastrozole and tamoxifen, drugs that were taken by post-menopausal women as part of the Anastrozole Tamoxifen Alone or in Combination (ATAC) trial. ATAC was a crucial breast cancer trial evaluating the use of aromatase inhibitors (AIs) in the adjuvant setting, with a median follow-up of over 10 years. The ATAC trial assessed the safety and efficacy of anastrozole+placebo, tamoxifen+placebo and anastrozole+tamoxifen in post-menopausal women undergoing treatment for invasive primary breast cancer The LATTE study aims to collect further follow-up information on a maximum of 2200 UK eligible patients, who were randomised to the monotherapy arms (anastrozole or tamoxifen) in the ATAC trial. The study’s primary objective is to provide additional efficacy and safety data on time to recurrence of breast cancer and death after recurrence. The secondary objectives include time to distant recurrence, cancer-specific survival, new breast primaries, other cancers, ischaemic cardiac and cerebrovascular events and hip (and other) fractures. Participants will be followed-up annually until at least 15 years median follow-up. It should be noted that the Research Ethics Committee (REC) and Confidentiality Advisory Group (CAG) have already approved the LATTE study for collection of vital HES, cancer registration and mortality data sets as part of this study. In 2010, results from 10-year follow-up from ATAC demonstrated that there is long-term superiority of anastrozole over tamoxifen as initial adjuvant therapy for post-menopausal women with hormone-sensitive early breast cancer. This paper demonstrated that there were significantly lower rates of local and distant recurrence, as well as reduced contralateral breast cancer in patients treated with anastrozole. However, in 2016 a recent preliminary analysis of the LATTE study demonstrated that the benefits of anastrozole do not continue long-term after 10 years in terms of reduced recurrence rates. The results also suggested that there was a larger reduction of new contralateral tumours with tamoxifen. However, the preliminary analysis was limited in that there was limited data with possible under reporting of vital events inked to the safety and efficacy endpoints; this therefore may diminish the effect of anastrozole. Queen Mary University of London (QMUL) therefore require extended cohort events, obtainable from HES, cancer registration and mortality data in order to conclude the long-term safety of either intervention. QMUL will then be able to integrate the pseudonymised LATTE data with the ATAC data sets in order to perform an analysis of the overall 20-year follow-up period.

Expected Benefits:

The data sets returned by NHS Digital will provide vital information on side effects, survival and breast cancer incidence. LATTE is currently the only study assessing the long-term effects of an aromatase inhibitor (AI) compared to tamoxifen, achieving a 20-year median follow-up period. Using the requested data sets, the LATTE Central Coordinating Office (CCO) will conduct research and analyses that will help provide further information on: - the efficacy of tamoxifen in reduction of breast cancer recurrences in post-menopausal women initially diagnosed with invasive breast cancer; - the efficacy of anastrozole in reduction of breast cancer recurrences in post-menopausal women initially diagnosed with invasive breast cancer; - the efficacy of anastrozole compared to tamoxifen in reduction of breast cancer recurrences in post-menopausal women initially diagnosed with invasive breast cancer; - the effect tamoxifen and anastrozole on all-cause mortality rate, cancer incidence, distant recurrence and new breast primaries; - the safety of tamoxifen in terms of occurrence of ischaemic cardiac and cerebrovascular events, as well as hip (and other) fractures; - the safety of anastrozole in terms of occurrence of ischaemic cardiac and cerebrovascular events, as well as hip (and other) fractures; - the safety of anastrozole compared to tamoxifen in terms of occurrence of ischaemic cardiac and cerebrovascular events, as well as hip (and other) fractures. The research will help inform public health bodies such as NICE on the long-term safety and efficacy of tamoxifen and anastrozole as adjuvant therapy. These analyses will enable patients and women who have been diagnosed with invasive breast cancer to make a more informed decision on the adjuvant treatment options available to them. The target data for these benefits is expected around 2020.

Outputs:

Data from a preliminary analysis was presented at the San Antonio Breast Cancer Symposium in December 2016 as a poster. QMUL plan to publish the main results from the LATTE cohort within 12-18 months after receipt of the NHS Digital data. This will enable them to report a more complete data set, with up-to-date information on recurrences, deaths, other primary cancers, and adverse events. To demonstrate a potential carry-over effect of anastrozole versus tamoxifen, long-term follow-up in excess of 10 years is essential. Therefore, after the initial publication in approximately 2020 QMUL plan to publish an updated manuscript on the benefits of AI therapy in 2022/2023. The main target audience for their data outputs are the patients with early breast cancer, and the medical professionals who can use the results for decision making. Further outputs and analyses of the LATTE study will be published in peer-reviewed medical journals such as The Lancet, The Lancet Oncology, Breast Cancer Research and Treatment and the British Journal of Cancer. Outputs are expected in 2020 when there is 10 years' of follow-up data available. The public will be made aware of the research progress through the following web page: https://www.qmul.ac.uk/wolfson/research-projects-a-z/current-projects/ The anticipated audiences of the above outputs are researchers, scientists, stakeholders for the wider project and research participants. Policy makers and public health bodies such as NICE will be targeted with the outputs of the study. NICE will be advised on the long-term safety and efficacy of tamoxifen and anastrozole as adjuvant therapy. These analyses will enable patients and women who have been diagnosed with invasive breast cancer to make a more informed decision on the adjuvant treatment options available to them. Data contained in any outputs will be aggregated with small numbers suppressed in line with the HES analysis guide. The funder will not have influence on the outcomes nor suppress any of the findings of the research.

Processing:

All organisations party to this agreement must comply with the Data Sharing Framework Contract, including requirements on the use (and purposes of that use) by "Personnel" (as defined within the Data Sharing Framework Contract i.e.: employees, agents and contractors of the Data Recipient who may have access to that data). The Centre for Cancer Prevention at QMUL will send LATTE cohort data, i.e. a list of LATTE study participants, to NHS Digital for linkage. The following identifiers will be sent to NHS Digital by the Centre for Cancer Prevention (CCP) team at QMUL: -Full Name, -Date Of Birth, -NHS Number, -Postcode, -Study ID. The data received by Centre for Cancer Prevention at QMUL will not be used for any purpose other than to meet objectives as stated in the trial protocol and will not be shared with any other third party or organisation. The data sets returned by NHS Digital to QMUL will contain identifiable data. This is so that QMUL can confirm the accuracy and strength of each linkage for LATTE participant in the study cohort. This ensures that all side effects, survival and cancer incidence data are correctly attributed to each LATTE participant, thus avoiding any errors which would invalidate the study. On receipt of the returned data set from NHS Digital, the Centre for Cancer Prevention at QMUL will link this data set to the data set contained in the applicant's LATTE study database via the full name, date of birth, NHS number and study ID. As mentioned, the data linkage enables the correct identification of the LATTE patients from the data set sent by NHS Digital. Once the patients are identified, researchers at QMUL will then update the participant entries in the LATTE study database with date and cause of death, cancer recurrence, diagnosis and coding, and any HES data relevant to the study (fractures, cardiovascular and thrombo-embolic events). Following the linkage and participant identification, all identifiers except the study ID will be removed from the data set returned by NHS Digital and stored as a reference for analysis until study completion. Processed data sets with all identifiers removed will be retained for analysis until study completion, following which it will be archived for 20 years. The original 'raw' data set returned by NHS Digital containing identifiable data will be stored on a separate server meeting NHS Digital security requirements, as per DARS Guidance Notes on Security for where Mortality Data is involved. Personal identifiable data are stored on the secure network and never on the local drives of unencrypted QMUL desktop PCs. QMUL creates back-ups of the data stored on its network. The encrypted backup tapes are stored offsite with Iron Mountain UK Ltd. The data is not accessible by any Iron Mountain employee. All personal identifiable data received at the Centre for Cancer Prevention are stored electronically on a database, local to and administered by substantive employees of QMUL only (no third parties). Personal identifiers of study participants are stored separately to the clinical data, with access strictly restricted to only QMUL substantive members of staff. Only these members of staff will have access to the personal identifiable data. Additionally, access to the personal identifiers on the separate database is controlled by separate username and password access and is controlled by the IT Department. The separate Mortality and HES servers are self-contained within the Centre for Cancer Prevention network within the QMUL network. They are firewalled from external connections and the rest of the network. All traffic through the checkpoint firewall is logged. Access to data will be from within the network using workstations that have a currently supported operating system which includes security patches. Users are not permitted to download the data from these workstations. No remote access (i.e. through a VPN/RDP connection) is permitted. No mobile devices will be used to access any data. The network is externally scanned on a regular basis. The 'raw' data sets will be stored until the data destruction date as per the Agreement with NHS Digital. The storage architecture is compliant with the NHS DIGITAL data sharing framework contract and once QMUL is issued with a Data Destruction notice, the data from all storage including backups can be securely and permanently removed within 14 days. Data can be securely wiped to NHS Digital standards (multi pass pattern wiped to at least HMG S5 Enhanced on site and if end of life, degaussed and physically destroyed). Under this agreement, it is not permitted to share the "raw" data with third parties. Only aggregated data with small numbers suppressed in line with the HES Analysis Guide is permitted to be shared.


Project 7 — DARS-NIC-55950-Y5Y2Y

Opt outs honoured: Y

Sensitive: Non Sensitive, and Sensitive

When: 2017/06 — 2017/08.

Repeats: One-Off

Legal basis: Health and Social Care Act 2012, Section 42(4) of the Statistics and Registration Service Act (2007) as amended by section 287 of the Health and Social Care Act (2012)

Categories: Anonymised - ICO code compliant, Identifiable

Datasets:

  • Hospital Episode Statistics Admitted Patient Care
  • Office for National Statistics Mortality Data

Objectives:

More than 150,000 high-risk patients undergo emergency surgery each year in the NHS, following which at least 90,000 patients develop complications resulting in over 20,000 deaths before hospital discharge. Patients who develop complications but survive, require in-hospital care for prolonged periods, suffering substantial reductions in functional independence and long-term survival. Recent data show that abdominal surgery and the need for surgery on an emergency basis are amongst the strongest factors associated with poor post-operative outcome. Around 35,000 patients present to NHS hospitals each year with precisely this pattern of risk and undergo a procedure known as ‘emergency laparotomy’. This term describes a major surgical procedure to treat an acute and often life threatening problem with the gut or other abdominal organ. Around 180 patients undergo emergency laparotomy in a typical NHS hospital each year with a 90-day mortality of 25%. There is considerable heterogeneity in standards of care between hospitals, including wide variations in the involvement of senior surgeons and anaesthetists and post-operative admission to critical care, which are associated with important differences in mortality rates. In 2010 the Department of Health commissioned a Royal College of Surgeons of England (RCS) working group to develop an integrated care pathway which could improve the quality of care for patients undergoing emergency laparotomy. An integrated care pathway was defined which represented an optimal standard of peri-operative care deliverable in all NHS hospitals. Examples of interventions included consultant led decision making and treatment, standards for diagnostic testing, structured post-operative surveillance, time limits for review of deteriorating patients and early admission to critical care. To date, there has been little systematic implementation of any component of the integrated care pathway. Most opinion leaders agree there is an urgent need for a national project to improve survival for emergency laparotomy patients. However, there is uncertainty about how best to achieve such improvement. Some question the benefits of quality improvement initiatives, pointing to the lack of robust clinical evidence of effectiveness, both in terms of generic methodologies advocated to improve quality, and the specific changes in patient care. There are examples where a discrete quality improvement intervention was associated with improved clinical outcomes. And experience from recent quality improvement initiatives has shown that challenges with quality improvement programmes can be overcome. However, doubts over the clinical effectiveness of quality improvement projects continue to limit the success of these initiatives. There is a clear need for robust clinical evidence to support or refute the use of this approach to improve clinical practice and, ultimately, patient outcome. The Healthcare Quality Improvement Partnership (HQIP) has commissioned a new National Emergency Laparotomy Audit (NELA), providing a unique opportunity to study the clinical effectiveness of a quality improvement project to implement an integrated peri-operative care pathway for emergency laparotomy patients. By providing a robust evidence base for quality improvement in peri-operative care, the findings of this work could accelerate implementation of care pathways for all categories of high-risk surgery with the potential for widespread improvements in survival affecting more than 170,000 NHS patients each year. QMUL have conducted a large pragmatic clinical trial of the effectiveness of a quality improvement project to implement a modified version of the RCS integrated care pathway to improve patient outcomes following emergency laparotomy. The trial is called Enhanced Peri-Operative Care for High-risk patients (EPOCH). Our aim is to provide the definitive evidence needed to inform practice in this area. TRIAL OBJECTIVES: 1. To evaluate the effect of a quality improvement intervention to promote the implementation of an integrated peri-operative care pathway on survival at 90 days following emergency laparotomy. 2. To assess the cost-effectiveness of the quality improvement intervention compared to ongoing clinical practice without the intervention. 3. To evaluate the long-term effects of the intervention on standards of care and mortality following emergency laparotomy in participating hospitals. Primary outcome measures: All cause mortality at 90 days following surgery Secondary outcome measures: All cause mortality at 180 days following surgery, duration of hospital stay and hospital re-admission within 180 days of surgery. In eight hospitals EQ-5D 3L will be collected and healthcare resource use data preoperatively, and at 90 and 180 days after surgery to perform a health economics analysis. In eight hospitals a Health Economics sub-study has been conducted. This involved patients who are already part of the NELA audit. QMUL consented patients and collected information (at 30, 90 and 180 days after surgery) about their quality of life and healthcare use using standardised questionnaires. The information that was recorded on paper questionnaires was entered into a secure, password protected database hosted by Queen Mary University London. No identifiable information was recorded in the database. Each patient in the Health Economics sub-study has a NELA ID which will be used to link with the main NELA dataset and data from ONS and HES. The team will collect EQ-5D 3L (a standardized questionnaire for measuring generic health status and quality of life) and healthcare resource use data preoperatively, and at 90 and 180 days after surgery to perform a health economics analysis which aims to assess whether implementing the quality improvement intervention is likely to be cost-effective on average and whether this varies between low and high mortality groups. As a national clinical audit funded by the Healthcare Quality Improvement Partnership (HQIP), the National Emergency Laparotomy Audit (NELA) has been established with the fundamental aim of improving the quality of patient care, and clinical outcomes. The EPOCH trial is an important example of how the data collected by NELA can be used to drive improvements in patient care.

Expected Benefits:

NELA has become a successful audit and is already tracking some improvements in patient outcomes nationally. However feedback from hospitals is that it can be difficult for them to know what changes to make that are most likely to lead to sustained improved outcomes for patients, or how best to bring about these improvements. EPOCH is built around a trial of a systematic and specific improvement intervention: a quality improvement programme. We have undertaken and will publish a great deal of evaluation of the quality improvement programme itself (both the ethnography and also through a process evaluation of the trial). Access to HES and ONS data is essential so that we can analyse and report the impact of the improvement intervention in terms of quality of care and patient outcome. Once we know the outcomes of the trial, we will be able to deduce evidence-based recommendations about what works and what does not work in improving care for this patient group, thereby allowing frontline clinicians and managers to make informed decisions about how best to improve patient care. Further to this, we will gain an understanding of quality improvement as a process in the NHS (in terms of feasibility and impact) which will be informative for commissioners and policymakers. Due to the synergy between EPOCH and NELA, with the latter providing an ongoing data set to support quality improvement, we could expect to begin to see this accelerated improvement commence within months of publication of the trial results. This is because hospitals will be able to track their improvements through ongoing participation in NELA. Publications will allow widespread dissemination of the findings amongst health professionals. Publishing in peer-reviewed journals will allow greater discussion of the strengths and weaknesses of the results, and will provide the benefit of peer-review of the work from third parties. Through dissemination in publications and at meetings (please see ‘Outputs’) results about did and didn’t work in the clinical care pathway will reach frontline clinicians (surgeons, anaesthetists and intensive care doctors). Therefore, we would expect to see measurable benefits, for emergency laparotomy patients nationwide, within 6-12 months of publication. We believe this work will influence trigger a sustained and widespread peri-operative quality improvement for all high-risk patients over a much longer period, with sustained and measurable benefits seen over a 2-10 year period from publication. A further measurable benefit is the anticipated contribution of the outputs produced as a result of the trial to clinical guidance and national policy within a 1-2 year period from publication.

Outputs:

The following outputs are planned: Final Report to Funder - 30th May 2017 Final EPOCH Investigators Meeting - summer 2017 Peer Reviewed Publications - summer 2017 Conferences and meetings - 2017 - ongoing Media – 2017 – ongoing NELA Website - 2017 Details of expected outputs: The main scientific report containing only aggregated data with small numbers supressed in line with the HES analysis guide will be sent to the Lancet journal for their consideration first. The Lancet have already published the trial protocol, and have expressed an interest in the work. Second choices would include the British Medical Journal, the New England Journal of Medicine, and the Journal of the American Medical Association. These are all general interest journals read by a wide range of healthcare workers worldwide. QMUL plan to invite all the co-investigators (from 92 hospitals) to a final EPOCH meeting where we will disseminate and discuss the findings. QMUL will also present the work at scientific meetings, and congresses. For example the ‘Annual Congress of Enhanced Recovery and Perioperative Medicine’ and the ‘Peri-Operative Medicine Congress’. QMUL will also disseminate the aggregated findings through the mainstream media (e.g. BBC news, Channel 4 News, Times Newspaper etc.) and also through social media (e.g. Twitter) with the support of our patient representatives. The main target audience will be surgeons, anaesthetists and intensive care doctors but also patients and their carers. The findings will also be published on the NELA and EPOCH websites. All outputs will aggregated with small numbers supressed in line with the HES analysis guide.

Processing:

The processing will follow these steps: Step 1 - RCS flow NHS number to NHS Digital, NHS Digital flow HES + ONS data to RCS with Objections upheld, this step has been completed under the agreement NIC-355855 and the flow is covered by s251 of the Care Act 2006. Step 2 - QMUL apply to NHS Digital for HES + ONS data (this application). The legal basis for the HES APC data is The Health and Social Care Act 2012 and the legal basis for the ONS data is s42(4) of the SRSA 2007. Step 3 - NHS Digital confirm to HQIP that QMUL have approval for the release HES + ONS data, once the application has been recommended for approval by DAAG Step 4 - RCS flow HES ID + study ID to NHS Digital to define cohort Step 5 - NHS Digital send study ID’s to RCS with objections upheld if relevant (copy in HQIP) Step 6 - QMUL apply separately to HQIP for audit data Step 7 - NHS Digital flow HES + ONS data to QMUL, (with study ID) with objections upheld if relevant Step 8 - HQIP authorise RCS to flow the audit data to QMUL Step 9 - RCS flow authorised audit data to QMUL Step 10 - QMUL will perform linkage of HES/ONS and Audit data based on a study id Step 11 - QMUL will perform linkage of HES/ONS and Audit data with Heath Economic sub-study data based on a study id The only identifiable field received by the EPOCH team is ONS Date of Death. The full Date of Death is required to be able to calculate survival at 2 time points (90 day, 180 day). The EPOCH team will not use ONS Date of Death to identify any individual patients. To be clear no attempt will be made at any point to re-identify and individual. In line with good practice, QMUL retains raw data to enable responses to journal peer reviews and re-analysis if required. Therefore Date of Death and Cause of Death will be retained for a 2 year period before being destroyed. In line with QMUL procedure, all other data will be archived for 20 years. The data received from HSCIC will not be linked back to the identifiable NELA database. An extract of annonymised NELA data will be linked to the HES-ONS data via the NELA ID. The annoymised NELA data and the HES-ONS data will also be linked to a Health Economics (HE) dataset via the NELA ID. The HE dataset does not contain any identifiers. Each patient in the Health Economics (HE) dataset also exists in the NELA dataset, and their NELA ID has been recorded in both datasets. The data has been collected as part of an ethically approved sub-study for the EPOCH trial, using patient consent. The EPOCH team Statisticians and Health Economists who will work on the linked dataset do not have access to the identifiable data set held by the RoCA or any identifiers held locally at hospitals. Only Queen Mary University Staff will have access to the data. The EPOCH team at QMUL will analyse the data in a secure environment with restricted access (called a safe haven) to assess the objectives listed. Outputs from the EPOCH analysis will only include aggregated data, no individual level data will ever leave the safe haven where the analysis is taking place .